The Latest Cardiac and Vascular News
Dr. Dhanasekharan joins Renovacor with extensive experience overseeing development, manufacturing and supply operations for biologics including AAV gene therapies PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), a biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice […]
Dr. Shin to help advance REN-001 into the clinic by leveraging nearly two decades of expertise in clinical development, academic research and medical practice PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan […]
NEW YORK, Sept. 1, 2021 /PRNewswire/ — Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) (“CHAQ”), a special purpose acquisition company sponsored by Chardan Capital Markets (“Chardan”), today announced the results for the proposals considered and voted upon by its stockholders at its special meeting held on September 1, 2021 (the “Special Meeting”), regarding the proposed business combination with Renovacor, Inc. […]
Dr. Killeen joins Renovacor from BioMarin where he led the discovery and development of AAV-based gene therapies for inherited cardiac diseases PHILADELPHIA, Aug. 25, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the […]
Dr. Zhang has over 20 years of experience in regulatory affairs, with over a decade specifically in the field of cell and gene therapy PHILADELPHIA, July 12, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, […]
Appointments to be effective upon closing of the previously announced merger between Renovacor and Chardan Healthcare Acquisition 2 Corp. PHILADELPHIA, June 29, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointments of […]
Former chief medical officer of MyoKardia to lead clinical development at Renovacor PHILADELPHIA and BOSTON, June 02, 2021 (GLOBE NEWSWIRE) — Renovacor, Inc. (“Renovacor”), an early‑stage biotechnology company developing adeno-associated virus (AAV)‑based gene therapies for devastating cardiovascular and central nervous system (“CNS”) diseases resulting from BAG3 gene variants, today announced the appointment of Marc Semigran, M.D., as […]
– Renovacor, Inc. has entered into a definitive merger agreement with Chardan Healthcare Acquisition 2 Corp. (NYSE: CHAQ) – – Upon closing, the combined company is expected to receive up to $116 million in proceeds and is expected to be listed on NYSE under the ticker symbol “RCOR” – – The business combination is expected […]
Former CEO of Freeline Therapeutics, Ltd. has outstanding international drug development, commercialization expertise, with focus on rare disease, gene therapy PHILADELPHIA–(BUSINESS WIRE)–Renovacor, Inc, a preclinical-stage biopharmaceutical company focused on developing transformative gene therapy-based treatments for cardiovascular disease, today announced the addition of Dr. Anne Prener to both the company’s board of directors and scientific advisory […]
– Funding supports preclinical development through IND submission for its BAG3 gene therapy, the first gene replacement product for genetic forms of dilated cardiomyopathy – Company announces leadership team and board of directors with leading scientists, physicians and experienced venture investors in cardiovascular and gene therapy fields August 14, 2019 10:11 AM Eastern Daylight Time PHILADELPHIA–(BUSINESS WIRE)–Renovacor, […]
